NO20003674L - Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase - Google Patents

Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Info

Publication number
NO20003674L
NO20003674L NO20003674A NO20003674A NO20003674L NO 20003674 L NO20003674 L NO 20003674L NO 20003674 A NO20003674 A NO 20003674A NO 20003674 A NO20003674 A NO 20003674A NO 20003674 L NO20003674 L NO 20003674L
Authority
NO
Norway
Prior art keywords
treatment
oral administration
solid pharmaceutical
leishmaniase
phosin
Prior art date
Application number
NO20003674A
Other languages
English (en)
Other versions
NO20003674D0 (no
Inventor
Juergen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Priority to NO20003674A priority Critical patent/NO20003674L/no
Publication of NO20003674D0 publication Critical patent/NO20003674D0/no
Publication of NO20003674L publication Critical patent/NO20003674L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO20003674A 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase NO20003674L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20003674A NO20003674L (no) 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
NO20003674A NO20003674L (no) 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Publications (2)

Publication Number Publication Date
NO20003674D0 NO20003674D0 (no) 2000-07-18
NO20003674L true NO20003674L (no) 2000-07-18

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003674A NO20003674L (no) 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Country Status (24)

Country Link
US (1) US6544551B1 (no)
EP (1) EP1051159B1 (no)
JP (1) JP2002501015A (no)
KR (1) KR100517399B1 (no)
CN (1) CN100413492C (no)
AT (1) ATE215817T1 (no)
AU (1) AU756805B2 (no)
BR (1) BR9814772A (no)
CA (1) CA2318260C (no)
CZ (1) CZ299229B6 (no)
DE (1) DE69804865T2 (no)
DK (1) DK1051159T3 (no)
ES (1) ES2175663T3 (no)
HU (1) HUP0004363A3 (no)
IL (1) IL136196A (no)
NO (1) NO20003674L (no)
NZ (1) NZ505648A (no)
PL (1) PL189654B1 (no)
PT (1) PT1051159E (no)
SI (1) SI1051159T1 (no)
SK (1) SK284839B6 (no)
TR (1) TR200001717T2 (no)
UA (1) UA68372C2 (no)
WO (1) WO1999037289A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
BR0215680A (pt) * 2002-04-26 2005-02-01 Rudolf Perl Composição farmacêutica oral estável
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
BR0313048A (pt) * 2002-07-30 2005-06-14 Zentaris Gmbh Uso de alquilfosfocolinas em combinação com medicamentos antitumorais
ES2297461T3 (es) 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
ES2523796T1 (es) 2004-10-08 2014-12-01 Forward Pharma A/S Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
ES2634094T3 (es) 2010-11-22 2017-09-26 Oblita Therapeutics Bvba Formas de dosificación sólida de oleil fosfolina
CN103732231B (zh) 2011-06-24 2020-04-10 格里生物公司 炎性病症的预防和治疗
JP2016515602A (ja) * 2013-04-08 2016-05-30 アカデミッシュ メディッシュ セントラム Ｉｂｄの治療に使用するためのミルテホシンまたはペリホシン
CA3018828C (en) 2014-09-17 2021-05-11 Steerlife India Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
WO2020208230A1 (en) 2019-04-12 2020-10-15 Oblita Therapeutics Bvba Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59778B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
CA2318260A1 (en) 1999-07-29
TR200001717T2 (tr) 2000-11-21
NO20003674D0 (no) 2000-07-18
NZ505648A (en) 2002-10-25
WO1999037289A1 (en) 1999-07-29
DK1051159T3 (da) 2002-08-05
CZ20002596A3 (cs) 2000-10-11
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
BR9814772A (pt) 2000-10-24
DE69804865D1 (de) 2002-05-16
JP2002501015A (ja) 2002-01-15
EP1051159A1 (en) 2000-11-15
UA68372C2 (en) 2004-08-16
PL189654B1 (pl) 2005-09-30
ATE215817T1 (de) 2002-04-15
PL342838A1 (en) 2001-07-16
CA2318260C (en) 2006-11-21
IL136196A (en) 2004-07-25
SI1051159T1 (en) 2002-10-31
HUP0004363A3 (en) 2002-12-28
CN100413492C (zh) 2008-08-27
EP1051159B1 (en) 2002-04-10
SK9862000A3 (en) 2000-11-07
CN1283111A (zh) 2001-02-07
AU6212198A (en) 1999-08-09
HUP0004363A2 (hu) 2001-04-28
KR100517399B1 (ko) 2005-09-28
AU756805B2 (en) 2003-01-23
KR20010034311A (ko) 2001-04-25
ES2175663T3 (es) 2002-11-16
DE69804865T2 (de) 2002-11-07
PT1051159E (pt) 2002-09-30
SK284839B6 (sk) 2005-12-01
US6544551B1 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
NO20003674D0 (no) Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase
EP1049459A4 (en) ORAL LIQUID COMPOSITIONS
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
BG105173A (en) Novel salt form of pantoprazole
HUP0301349A2 (hu) IL-11-tartalmú készítmények
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
SE8006550L (sv) Farmakologisk komposition, samt sett for dess framstellning
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
UA32939A (uk) Сульфокамфокаїн, спосіб його виготовлення і спосіб підготовки обладнання для виготовлення сульфокамфокаїну
EP0817643A4 (en) COMPOUNDS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application